MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
Gene Therapy Stocks$254.97
0.18%4:00PM 05/26/2023
The list of companies include RCKT-Rocket Pharmaceuticals Inc, ABEO-Abeona Therapeutics Inc, RGNX-Regenxbio Inc, BMRN-Biomarin Pharmaceutical Inc., RARE-Ultragenyx Pharmaceutical Inc., QURE-uniQure N.V., VYGR-Voyager Therapeutics Inc, BNTC-Benitec Biopharma Inc, SGMO-Sangamo Therapeutics Inc, ADVM-Adverum Biotechnologies Inc, EDIT-Editas Medicine Inc, NTLA-Intellia Therapeutics Inc, CRSP-CRISPR Therapeutics AG, AVRO-AvroBio Inc, MGTX-MeiraGTx Holdings plc, BLUE-Bluebird bio Inc, FIXX-Homology Medicines Inc, SLDB-Solid Biosciences Inc, CAPR-Capricor Therapeutics Inc, SRPT-Sarepta Therapeutics Inc
Latest intraday update before market close @ 19:45:53 PM 05/26/2023
Summary :
Average return is down -0.0%
Median return is down -0.3%
8 out of 18 stocks are up (limited to those with intraday pricing feeds).

Aggregated price index

Aggregated price index with volume information

Summary:

  • Gene Therapy stocks up 0.2% on average while median return up 0.0% in a day
  • Gene Therapy stocks down 4.3% on average while median return down 3.7% in a week
  • Gene Therapy stocks up 12.2% on average while median return up 7.5% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks

Click on + to show price series and click on ticker for stock detail page

Ticker
1 Day Return
1 Week Return
1 Month Return
PE Ratio
PE/G
P/B (mrq)
P/S (ttm)
Earning Growth
MarketCap
Short %
Held By Institutions %
RSI
Price Pattern
Resist Support
Days Since Channel Change
Channel Slope (daily rate %)
MGTX4.4%
-13.0%
23.8%
-3.413.0842.65390.3M1%63%52\/\176-0.1%
ORTX3.2%
-6.0%
5.2%
2.03230.84944.8M69%49\/1520.1%
SLDB2.7%
2.7%
27.0%
1.70129.31121.2M10%73%63\150-0.3%
AVRO2.6%
52.2%
32.5%
1.5352M12%99%62\/1760.4%
BLUE2.3%
-4.8%
-3.3%
-2.50.071.869.25380.4M10%80%42\/\128-0.4%
RCKT1.6%
-3.3%
21.6%
-1.585.551.7B19%97%56/\/1760.2%
CRSP1.3%
4.1%
31.7%
-9.641.335.369325.585.1B6%58%60/\351-0.1%
FIXX1.0%
-3.8%
7.7%
0.581.7212.4657.2M7%63%49\176-0.3%
VYGR0.9%
-8.5%
65.5%
4.81.241.06525M9%70%61\/Above resistance1130.4%
EDIT0.2%
-2.4%
13.5%
-2.863.7926.59627.2M18%75%51/\176-0.3%
RARE-0.2%
-0.1%
17.4%
-4.86-1.066.0719.533.5B13%102%61/\-176-0.1%
BMRN-0.3%
-3.7%
-4.3%
233.27-4.763.598.11-79%16.6B8%98%33/\/Below support1760.1%
RGNX-0.3%
-9.2%
-2.4%
-2.92-3.722.8910.30790.9M11%85%43\/\527-0.1%
NTLA-0.6%
-7.2%
7.4%
-7.26-1.059.44100.433.4B12%88%43/-\-176-0.2%
QURE-0.9%
-8.6%
2.5%
-5.816.5339.87925.7M8%96%40\/1760.1%
SRPT-1.6%
-14.9%
3.7%
-9.99-0.1111.8211.0411.8B12%84%43\/-/At support1220.2%
ABEO-2.2%
1.3%
0.3%
1.5916.8459M7%35%52-\/-1760.0%
CAPR-3.0%
0.2%
16.2%
3.33734.59113M8%19%58/-176-0.0%
SGMO-5.3%
-2.3%
-21.3%
-1.580.523.4612.42215.6M12%56%39/\351-0.2%

* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.

* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.

* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.

Related ETFs (click on ticker for stock detail page)

leak data

  • 1M winners are : Winners for past month are $VYGR 65.5%, $CRSP 31.7%, $SLDB 27.0%, $MGTX 23.8%, $RCKT 21.6%
  • 1M losers are : Losers for past month are $RGNX -2.4%, $BLUE -3.3%, $BMRN -4.3%, $SGMO -21.3%
  • 1W winners are : Winners for past week are $CRSP 4.1%, $SLDB 2.7%, $ABEO 1.3%, $CAPR 0.2%
  • 1W losers are : Losers for past week are $VYGR -8.5%, $QURE -8.6%, $RGNX -9.2%, $MGTX -13.0%, $SRPT -14.9%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 25.4%, for the past 3 months is 27.1%

In the past month for a 5 days rolling window, the highest corrrelation is 41.5%, the lowest correlation is 6.3%, the latest correlation is 41.5%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 69.8% between BMRN and NTLA

The lowest correlation is -27.6% between ABEO and FIXX

Stock news

    05/26/2023BMRN
    Why Is BioMarin (BMRN) Down 4% Since Last Earnings Report?

    BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    05/25/2023CRSP
    2 Top Trends to Invest $5,000 in Right Now

    Gene-editing healthcare therapies and renewable energy are two of the strongest trends today and for the next few years. Both sectors are worthy of sizable investments, particularly if you're looking to make long-term investments. CRISPR (clustered regularly interspaced short palindromic repeats) gene editing was discovered in 2012, and has the potential to revolutionize some aspects of health care.

    05/25/2023CRSP
    Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health

    CRISPR Therapeutics (NASDAQ: CRSP) and Teladoc Health (NYSE: TDOC) both score a win when it comes to innovation in healthcare. CRISPR has developed a gene-editing approach that aims to fix faulty genes responsible for disease. Teladoc leads in telemedicine, allowing patients to visit doctors from the comfort of an armchair at home.

    05/25/2023BMRN
    14 Best Biotech Stocks To Buy According To Hedge Funds

    In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]

    05/25/2023ABEO
    Q1 2023 Abeona Therapeutics Inc Earnings Call and Portfolio Update Conference Call

    Q1 2023 Abeona Therapeutics Inc Earnings Call and Portfolio Update Conference Call

    05/24/2023SRPT
    Sarepta Therapeutics Dives On An Unexpected Holdup For Its Gene Therapy

    The FDA pushed back its review of a highly anticipated gene therapy from Sarepta Therapeutics on Wednesday, prompting SRPT stock to tumble.

    05/24/2023SRPT
    Why Shares of Sarepta Therapeutics Are Dropping Wednesday

    Shares of Sarepta Therapeutics (NASDAQ: SRPT), which focuses on genetic treatments for rare diseases, were down 11.5% Wednesday afternoon after the Food and Drug Administration (FDA) pushed back its Prescription Drug User Fee Act (PDUFA) date on a Duchenne muscular dystrophy therapy candidate. The biotech stock is up less than 1% so far this year. The FDA gave Sarepta good news and bad news on Wednesday regarding the company's gene transfer therapy, SRP-9001 (delandistrogene moxeparvovec), des...

    05/24/2023SRPT
    FDA Extends Review For Sarepta Therapeutics' Duchenne Gene Therapy By Couple Of Weeks

    The FDA informed Sarepta Therapeutics Inc (NASDAQ: SRPT) that it requires modest additional time to complete the review of its SRP-9001 (delandistrogene moxeparvovec) for Duchenne muscular, including final label negotiations and postmarketing commitment discussions. Last week, FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of Sarepta's SRP-9001. The agency has extended the review date from May 29 to June 22. Following discuss

    05/24/2023SRPT
    2 Under-the-Radar Biotech Stocks to Buy in 2023

    With that said, let's consider two biotech stocks, neither of which is a household name, that could deliver solid returns over the next five years and more: Exelixis (NASDAQ: EXEL) and Sarepta Therapeutics (NASDAQ: SRPT). Oncology is one of the most fiercely competitive therapeutic areas in the biotech industry. Exelixis, a mid-cap biotech, is just a small player in the field.

    05/24/2023SRPT
    UPDATE 2-FDA defers decision for Sarepta's gene therapy to June 22 from May 29

    Sarepta Therapeutics Inc said the U.S. drug regulator deferred an accelerated approval decision for its gene therapy for a muscle wasting disorder to June 22 from May 29, sending its shares tumbling 16% before the bell. The deferral followed a meeting of the regulator's external advisers less than two weeks ago, where the panel narrowly backed an accelerated approval for the Duchenne muscular dystrophy therapy with 8-6 votes. The regulator, however, indicated that it could potentially grant an...